Mometasone Furoate Accord-Uk (Mometasone Furoate)

Mometasone furoate penetrates skin cells and binds to glucocorticoid receptors, modifying gene expression to suppress pro‑inflammatory cytokines, inhibit leukocyte migration, and decrease vascular permeability. This anti‑inflammatory and immunosuppressive action reduces the signs and symptoms of skin inflammation.

The appropriate dose and frequency of Mometasone Furoate Accord-Uk are determined by the prescribing healthcare professional based on the specific condition, severity, patient age and treatment area. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

Safety data for mometasone furoate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians should evaluate each case individually and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency class III topical corticosteroid, offering stronger anti‑inflammatory effects than low‑potency agents like hydrocortisone but less potency than class I steroids such as clobetasol. It provides a balance of efficacy and safety for moderate to severe dermatoses when used as directed.

Store the product at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

Apply a thin layer of the cream or ointment to the affected skin area once or twice daily, as instructed by the prescriber. Gently rub in until fully absorbed, and wash hands after application unless treating the hands themselves.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic corticosteroid effects such as adrenal suppression, especially with extensive or prolonged use. Patients should report any unusual skin changes, signs of infection or systemic symptoms to their healthcare provider promptly.

Individuals with known hypersensitivity to mometasone furoate or any formulation components should avoid the product. It is also contraindicated on infected skin that has not been treated, on large body surface areas without medical supervision, and in patients where systemic corticosteroid exposure is undesirable.